Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has completed, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Gray Zone Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-06-12